BIO-RAD LABORATORIES-A (BIO)

US0905722072 - Common Stock

342.16  +1.1 (+0.32%)

After market: 342.16 0 (0%)

Buy % Consensus

73

ChartMill assigns a Buy % Consensus number of 73% to BIO. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 380.97. This target is 11.34% above the current price.
BIO was analyzed by 11 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about BIO.
In the previous month the buy percentage consensus was at a similar level.
BIO was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

Price Target & Forecast

Price Low Median Mean High 342.16318.15377.40380.97468.30 - -7.02% 10.30% 11.34% 36.87%

Related screens

Up and Down Grades
Date Firm Action Rating
2024-10-01 Citigroup Upgrade Neutral -> Buy
2024-08-27 Wells Fargo Initiate Equal-Weight
2024-08-16 RBC Capital Reiterate Outperform -> Outperform
2024-08-02 RBC Capital Maintains Outperform -> Outperform
2024-08-02 Citigroup Maintains Neutral -> Neutral
2024-05-08 UBS Maintains Buy -> Buy
2024-04-03 Citigroup Downgrade Buy -> Neutral
2024-02-16 UBS Maintains Buy -> Buy
2024-02-16 RBC Capital Maintains Outperform -> Outperform
2023-12-07 UBS Initiate Buy
2023-08-07 Wells Fargo Maintains Overweight -> Overweight
2023-08-04 RBC Capital Maintains Outperform -> Outperform
2023-08-04 Credit Suisse Maintains Outperform -> Outperform
2023-06-16 Wells Fargo Initiate Overweight
2023-05-08 RBC Capital Maintains Outperform
2023-05-08 Citigroup Maintains Buy
2023-05-05 Credit Suisse Maintains Outperform
2023-02-17 RBC Capital Maintains Outperform
2023-02-17 Credit Suisse Maintains Outperform
2022-12-07 RBC Capital Initiate Outperform
2022-10-28 Credit Suisse Maintains Outperform
2022-08-25 Credit Suisse Initiate Outperform
2022-07-08 Citigroup Maintains Buy
2021-07-30 Wells Fargo Maintains Overweight
2021-02-12 Citigroup Maintains Buy